Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Idiopathic pulmonary fibrosis (IPF) is a life threatening condition of the lungs where tissue becomes thickened, stiff, and scarred over a period of time. The lungs lose their ability to take in and transfer oxygen into the bloodstream. It affects as many as 14–43 people per 100,000 worldwide, and while research has identified key factors in the development of IPF, no direct cause is known. Acute IPF exacerbations are defined as rapid deteriorations of symptoms within days or weeks. Reducing the risk of acute exacerbations is a key treatment goal in the management of all patients with IPF.